ITGA2 and pancreatic neoplasm: Previous studies have reported that ITGA2 is closely related to chemotherapy sensitivity and that its high expression mediates gemcitabine resistance in pancreatic cancer [13], 5-FU resistance in colorectal cancer [22], and 5-FU and ADR resistance in gastric cancer [23].